PubMed · 1993 · 140 citations · 40 references
MedicineMolecular BiologyOncologyBreast OncologyMetastasisMolecular OncologyBreast Cancer OncologyMalignant NeoplasmsMetastatic Breast CancerTumor AntigensTumor-associated AntigensCancer AntigensCd44 ExpressionGlycoprotein Tumor AntigensGlycoprotein Tumor MarkersTumor-associated Glycoproteins
To investigate the clinical significance of CD44 expression (lymphocyte-homing receptor) in adenocarcinoma, deparaffinized sections from 198 female breast carcinomas were stained with Hermes-3 MoAb for CD44 glycoprotein. In 16% of the cancers most (> or = 90%) of the cancer cells stained positively for CD44, whereas the rest of the cancers were either heterogenous (46%) or negative (38%) in CD44 staining. Cancers with > 50% CD44 positive cells were more often poorly differentiated (grade 3) than those with < or = 50% positive cells (38 vs. 19%, P = 0.006), they had higher mitotic counts (P = 0.04), and were more often estrogen receptor negative (52 vs. 31%, P = 0.01). Among ductal not otherwise specified cancers and node-positive cancers strong CD44 expression was associated with poor outcome (P = 0.05 and 0.02, respectively). However, CD44 expression was not an independent prognostic factor in these subgroups in a multivariate analysis. Unlike in lymphomas the unfavorable prognosis associated with CD44 expression may not be explained by the greater metastatic potential of CD44-positive cells, because the difference in mortality between the groups appeared to diminish with time, and CD44 positivity was associated with aggressive histological features.
40
CD44 is the principal cell surface receptor for hyaluronate
Alejandro Aruffo, Ivan Stamenkovic, Michael Melnick et al. · Cell · 1990 · 2.5K citations
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
Ursula Günthert, Martin Hofmann‐Apitius, W. Rudy et al. · Cell · 1991 · 1.7K citations